 Home > Active Ingredient News > Study of Nervous System > Nat Aging: Alzheimer's disease vaccine is here!

Nat Aging: Alzheimer's disease vaccine is here!

 Last Update: 2021-06-21
 Source: Internet
 Author: User

Tags

cardiovascular disease treatment

amyloid beta protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The neuropathological features of Alzheimer's disease are the deposition of amyloid-β and the accumulation of tau protein
.

The pathology of neurofibrillary tau is closely related to key aspects of the neurodegenerative process

According to current understanding, neurons that initially undergo neurofibrillary disease will spread tau aggregates, which is similar to prions
.

Subsequently, as the tau seeds produced by the affected neurons enter healthy but fragile cells, where they change the physiological tau conformation, the tau pathology spreads in the brain along the neuronal pathway

More and more evidences show that aggregated tau, whether in free form or exosomal form, can be transferred from donor cells (neurons or glial cells) to recipient cells through various channels, including recipients Mediated (heparin sulfate proteoglycan, LDL receptor related protein 1) or non-receptor-mediated endocytosis/microprotein phagocytosis or transport via nanotubes (in vitro data)
.

Targeting tau is a potential treatment for AD

Recently, researchers reported the results of ADAMANT, a 24-month double-blind, parallel-arm, randomized phase 2 multicenter placebo-controlled trial in which AADvac1 is an active peptide vaccine designed to target AD Pathological tau protein (EudraCT 2015-000630-30)
.

Double-blind, parallel-arm, randomized Phase 2 multicenter placebo-controlled trial Double-blind, parallel-arm, randomized Phase 2 multicenter placebo-controlled trial AADvac1 is an active peptide vaccine designed to target the pathological tau protein AADvac1 in AD It is an active peptide vaccine designed to target the pathological tau protein of AD

During the trial, 11 doses of AADvac1 were administered to patients with mild AD dementia, each dose of 40 micrograms
.

The main goal is to evaluate the safety and tolerability of long-term AADvac1 treatment

immunity

The antibody response of AADvac1 treatment for more than 104 weeks shows that it has strong immunogenicity
.

The antibody response of AADvac1 treatment for more than 104 weeks shows that it has strong immunogenicity

AADvac1 is safe and well tolerated.

Original source:

Petr Novak et al.

et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.